1. Home
  2. PLUS vs NKTR Comparison

PLUS vs NKTR Comparison

Compare PLUS & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ePlus inc.

PLUS

ePlus inc.

HOLD

Current Price

$91.17

Market Cap

2.3B

Sector

Technology

ML Signal

HOLD

Logo Nektar Therapeutics

NKTR

Nektar Therapeutics

HOLD

Current Price

$67.90

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLUS
NKTR
Founded
1990
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.2B
IPO Year
1996
1996

Fundamental Metrics

Financial Performance
Metric
PLUS
NKTR
Price
$91.17
$67.90
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$146.67
AVG Volume (30 Days)
241.1K
1.2M
Earning Date
05-21-2026
05-07-2026
Dividend Yield
1.20%
N/A
EPS Growth
24.20
N/A
EPS
5.03
N/A
Revenue
$2,442,549,000.00
$307,711,000.00
Revenue This Year
$19.83
N/A
Revenue Next Year
$4.36
N/A
P/E Ratio
$17.82
N/A
Revenue Growth
18.07
86.00
52 Week Low
$62.11
$21.02
52 Week High
$93.98
$109.00

Technical Indicators

Market Signals
Indicator
PLUS
NKTR
Relative Strength Index (RSI) 67.08 51.52
Support Level $86.41 $64.30
Resistance Level $93.17 $76.67
Average True Range (ATR) 3.07 4.29
MACD 1.09 0.82
Stochastic Oscillator 90.06 45.29

Price Performance

Historical Comparison
PLUS
NKTR

About PLUS ePlus inc.

ePlus Inc is a provider of technology solutions across the IT spectrum, spanning security, cloud, data center, networking, collaboration, AI, service provider, and critical infrastructure, and emerging solutions, to domestic and foreign organizations across all industry segments. Its solutions leverage a broad range of professional, consultative, and managed services across the technology spectrum. The company possesses top-level engineering certifications with a broad range of IT technologies that enable the company to offer multi-vendor IT solutions that are optimized for each of its customers' specific requirements. It also offers a wide portfolio of technology and other capital asset financing solutions to customers across commercial and government enterprises, designing programs.

About NKTR Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

Share on Social Networks: